Amneal launches delayed-release proton pump inhibitor for GERD
Amneal Pharmaceuticals will start shipping its branded Esomeprazole Strontium 49.3 mg delayed-release capsules on December 18 to three major U.S. wholesalers. Its capsules contain the same active ingredient, esomeprazole, in a different salt form as found in Nexium (esomeprazole magnesium).
Amneal Pharmaceuticals will start shipping its branded Esomeprazole Strontium 49.3 mg delayed-release capsules on December 18 to 3 major US wholesalers. Its capsules contain the same active ingredient, esomeprazole, in a different salt form as found in Nexium (esomeprazole magnesium).
The 49.3 mg strength of Esomeprazole Strontium capsule is equivalent to the 40 mg of esomeprazole base in the Nexium dose. Esomeprazole Strontium capsules will be available in 30-count bottles, according to Amneal.
Esomeprazole Strontium is a proton pump inhibitor indicated for short-term use in adults for the treatment of gastroesophageal reflux disease (GERD), risk reduction of NSAID-associated gastric ulcer, H. pylori eraditiona to reduce the risk of duodenal ulcer recurrence, and pathological hypersecretory conditions.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
